UAE Aid Agency Explores Partnership with Swiss Counterpart to Boost Global Humanitarian Impact
The discussions took place on the sidelines of the Dubai International Humanitarian Aid and Development Conference and Exhibition (DIHAD), where both sides explored opportunities to collaborate on critical global challenges. The goal is to align with the United Nations Sustainable Development Goals and expand the reach of humanitarian assistance to vulnerable communities worldwide.
Dr. Tareq Ahmed Al Ameri, Chairman of the UAE Aid Agency, and Patricia Danzi, Director-General of the Swiss agency, led the meeting. Both parties emphasized the need for coordinated action to enhance the efficiency and effectiveness of aid delivery.
The talks focused on areas including education, healthcare, environmental sustainability, and infrastructure development. By pooling resources and expertise, the agencies aim to improve living conditions and create long-term, sustainable impact in underserved regions.
This initiative marks a step toward deeper international collaboration in humanitarian affairs, as the UAE continues to position itself as a key global player in aid and development.
News Source: Emirates News Agency
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Gulf Today
11-08-2025
- Gulf Today
ADFD: Strategic partner in advancing comprehensive Arab development
The Abu Dhabi Fund for Development (ADFD) has reinforced its position as one of the most prominent contributors in supporting economic and social progresses efforts in Arab countries, financing strategic projects that promote stability, drive growth and enhance quality of life, underscoring the UAE's steadfast commitment to its Arab neighbours. In recent years, the fund has broadened its engagement across the Arab region, translating its mission into tangible projects in vital sectors such as healthcare, energy and infrastructure, areas that are fundamental to the stability and future of communities. Each project represents a solid step forward in the path to comprehensive development. According to its 2024 Annual Report, ADFD's cumulative development financing reached Dhs216.5 billion, benefiting 107 countries across various continents. This total comprises Dhs157 billion in concessional loans, Dhs57.6 billion in government grants, and Dhs1.9 billion in direct contributions. In statements to the Emirates News Agency (WAM), the Fund said that in 2024 it managed six UAE government grants to Arab nations worth a combined Dhs810 million, benefiting Jordan, Morocco, Yemen and Mauritania. Jordan received more than Dhs452 million for three key projects: a national digital health transformation programme, budget support, and a reading skills development programme. Morocco was allocated Dhs129 million for the expansion of the Oued Akrach - Ain Aouda Road, Yemen received Dhs45 million for a solar power project in Socotra, and Mauritania was granted Dhs184 million for the Applied Sciences College. Among the standout initiatives is Jordan's recently launched 'Jordan Digital Health Centre', which aims to connect healthcare centres and create an integrated electronic medical records management system through a unified digital platform, to enhance Jordan's healthcare sector in delivering remote care services aligned with international standards. Phase one has already linked five hospitals in remote areas and three health centres across the kingdom, reflecting the depth of the UAE–Jordan cooperation in advancing development through digital innovation. The fund also oversees UAE grants under the Arab Gulf Programme for Development (AGFUND), with Dhs4.6 billion allocated each to Jordan and Morocco between 2012 and 2024 to support projects that directly improve citizens' lives. In the same period, Bahrain received an Dhs9.2 billion grant under the GCC Development Programme for major projects across various sectors. In 2025, ADFD has continued to implement high-impact investment projects across the Arab world. These include Egypt's 'Sofitel Legend Pyramids Giza' to support the tourism sector, an integrated tourism venture in Salalah, Oman, and the expansion of Bahrain International Airport. The fund has also advanced renewable energy in the Comoros through a solar power station, supported community stability in Somaliland with a housing project, and in June signed a financing agreement with the GCC Interconnection Authority for a strategic project to strengthen regional energy security. By championing strategic, high-value initiatives, the Abu Dhabi Fund for Development continues to act as a vital bridge for progress, reflecting the UAE's enduring commitment to spreading stability and prosperity across the Arab region and beyond. WAM
Web Release
01-08-2025
- Web Release
Neovie Concept Hosts Grand Launch Event, Introducing 'Luxury Aesthetic Within Your Reach' to Lebanon
Neovie Concept, the newest name in luxury medical aesthetics, marked its official debut on Wednesday, July 23, with a grand launch event at its flagship location in Waterfront City, Business Park 4, Dbayeh. The exclusive celebration welcomed over 400 guests, including VIPs, media, and leading figures in the aesthetics industry, all gathered to witness the arrival of a groundbreaking new approach to aesthetic care—where refined luxury meets medical precision in a setting thoughtfully designed around the guest. Neovie Concept is more than a clinic—it's a holistic aesthetic destination that redefines the client journey through a seamless blend of accessibility, personalization, and medical excellence. Spanning 900 square meters, the center features ten state-of-the-art treatment rooms, each offering a curated menu of advanced services, including skincare, injectables, body contouring, and regenerative therapies—all performed by a team of elite medical professionals dedicated to delivering results with care and discretion. As part of its vision to make elevated care more widely available, Neovie introduced 'Privé'- its Gold Membership model, providing all clients with a 30% preferential rate starting from their very first visit. This is not a limited-time offer, but a long-term commitment to inclusivity, designed to make premium aesthetic care more accessible—without compromise. A major highlight of the evening was the unveiling of the exclusive Dr Burgener Switzerland treatment space—now available for the first time in Lebanon. Direct from its prestigious Clinic and laboratories in Switzerland, Dr Burgener brings to Neovie a range of high-performance, science-based skincare treatments. Known globally for merging medical-grade innovation with luxury rituals, the brand offers advanced anti-aging facials, skin repair therapies, and personalized protocols that combine biotechnology with natural active ingredients. This exclusive collaboration allows guests at Neovie to experience the very best of Swiss skincare excellence in a luxurious and results-driven setting. 'Our goal with Neovie was to reshape the aesthetic journey—to create something far more intentional and personal than a traditional clinic,' said Dr. Ibrahim Melki, Medical Director of Neovie. 'Every detail, from the medical protocols to the ambiance, was designed to honor individuality while delivering world-class results in a space that feels both luxurious and welcoming.' With its calming interiors, no-wait-time policy, and a commitment to discreet, guest-centered service, Neovie Concept offers more than treatments—it offers a sanctuary where clients feel seen, understood, and truly cared for. The launch event marked not just the opening of a new space, but the introduction of a concept that prioritizes people over procedures. As Neovie enters the Lebanese aesthetic scene, it does so with a clear and powerful message: Luxury Aesthetic Within Your Reach.
Gulf Today
24-07-2025
- Gulf Today
5 years after COVID, pharma shares languish
Global healthcare stocks have not been this cheap in decades and fund inflows into the sector are picking up, yet the shares remain in the doldrums, highlighting uncertainty over drug pricing policies since Donald Trump returned to the White House. Pharma companies' earnings outlook is being obscured by concerns over revived "most-favored-nation" drug pricing rules in the lucrative US market and potential 200% tariffs on pharma imports into the US. Money flooded into drugmakers' shares during the COVID-19 pandemic but more recently there has been an exodus as investors shifted into Big Tech, leaving the sector cheap but unloved, reported Reuters. At 15.9 times forward earnings, healthcare trades 11% below its long-term average and 20% below global equities, its steepest discount in 16 years, just above a record discount in 2009, based on LSEG Datastream data. "We've moved from cautious optimism to cautious pessimism," said Stephanie Aliaga, global market strategist at J.P. Morgan Asset Management in New York. "Valuations have gotten even cheaper, but for a reason," she added, referring to intensifying US policy risks. But some investors are starting to look past the Washington policy fog and at long-term positive drivers, such as aging populations, RNA-based therapeutics, and breakthroughs in weight-loss and diabetes drugs, Reuters reported. Alberto Conca, CIO at Swiss wealth manager LFG+ZEST, has been adding exposure to pharma, biotech and medtech in recent weeks, drawn by strong cash-flow yields and the prospect of US rate cuts boosting this rate-sensitive sector. Interest rate cuts typically support healthcare by lowering R&D funding costs and boosting the value of future cash flows. "These are quality companies with good growth and defensive features being priced as if we're heading into an 'Armageddon scenario', which I believe is unlikely," he said. UK-based M&G Investments has also been selectively adding to healthcare, according to its latest allocation report. Healthcare funds have seen net inflows since 2024, more than reversing the outflows from late 2022 through 2023, fund tracker EPFR data shows. Although year-to-date, inflows total $7.2 billion, down 41% from last year. Innovation is accelerating, pipelines are maturing and M&A is showing signs of picking up — yet stock prices are unmoved. Whether that represents a buying opportunity or a value trap hinges on how and when the policy uncertainty clears, investors said. Historically, healthcare has traded at a modest premium to world stocks, thanks to its defensive profile and steady earnings. But that narrative has unravelled under political pressure from Washington and investors' love of Big Tech. Over the past three years, US healthcare has underperformed the S&P 500 by more than 60 percentage points, making it the worst sectoral performer on Wall Street. Its valuation has deepened to a near-record 27% discount, from parity to the S&P in 2023. "Markets don't like uncertainty, and that shows up in valuations," said Eddie Yoon, healthcare sector leader and portfolio manager at Fidelity Investments in Boston. "Being cheap isn't necessarily a reason to buy. You need a catalyst." For now, that catalyst is elusive. The policy uncertainty makes it difficult to forecast future earnings, he said, though he hopes for more clarity by year-end - potentially also paving the way for more M&A in the industry. Talks with the Trump administration have yet to clarify how and when drug prices will fall, executives from Eli Lilly and Merck said at a May industry conference.
